ClinicalTrialsFinder

HR+/HER2- Advanced Breast Cancer Clinical Trials in Toronto, Ontario

1 recruitingToronto, Ontario, Canada

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

HR+/HER2- Advanced Breast CancerTriple Negative Locally Advanced Non-resectable Breast Cancer
Marengo Therapeutics, Inc.50 enrolled8 locationsNCT06827613